Konecny et al. illustrated a quantitative relationship between HER2/neu and hormone receptors in breast cancer cell lines, explaining the relative resistance of HER2/neu-positive, HR-positive tumors to hormone therapy [16]. This evidence concerns the gene ERBB2 and breast carcinoma.